Application-Specific R&D Capabilities and the Advantage of Incumbents: Evidence from the Anticancer Drug Market

References

• American Cancer Society Cancer facts & figures. (2000) . Accessed March 10, 2008, http://www.cancer.org/downloads/STT/F&F00.pdfGoogle Scholar
• Amit R., Schoemaker P. J. H. Strategic assets and organizational rent. Strategic Management J. (1993) 14(1):33–46Crossref, Google Scholar
• Ayala F. A. Combustion lean limits fundamentals and their application to a SI hydrogen-enhanced engine concept. (2006) . Unpublished doctoral dissertation, Massachusetts Institute of Technology, CambridgeGoogle Scholar
• Azoulay P. Capturing knowledge within and across firm boundaries: Evidence from clinical development. Amer. Econom. Rev. (2004) 94(5):1591–1612Crossref, Google Scholar
• Barney J. B. Firm resources and sustained competitive advantage. J. Management (1991) 17(1):99–120Crossref, Google Scholar
• Bear Sterns Biotechnology: Cancer—Concepts and controversies, Volume 1. (2002) . Report, Bear Sterns, New YorkGoogle Scholar
• Capdeville R., Buchdunger E., Zimmermann J., Matter A. Glivec (STI571, Imanitib), a rationally developed, targeted anticancer drug. Nature Rev. Drug Discovery (2002) 1:493–502Crossref, Google Scholar
• Carroll G. R., Bigelow L. S., Seidel M. D. L., Tsai L. B. The Fates of de novo and de alio producers in the american automobile industry 1885–1981. Strategic Management J. (1996) 17(Special Issue):117–137Google Scholar
• Chabner B. A., Roberts T. G. Timeline: Chemotherapy and the war on cancer. Nature Rev. Cancer (2005) 5:65–72Crossref, Google Scholar
• Christensen C.The Innovator's Dilemma (1997) (Harvard Business School Press, Boston) Google Scholar
• Conner K. R. Strategies for product cannibalism. Strategic Management J. (1988) 9(Special Issue):9–26Crossref, Google Scholar
• Cooper A. C., Schendel D. Strategic responses to technological threats. Bus. Horizons (1976) 19(1):61–69Crossref, Google Scholar
• Dierickx I., Cool K. Assets accumulation and sustainability of competition advantage. Management Sci. (1989) 35(12):1504–1514Link, Google Scholar
• Graham S. J. H., Higgins M. J. The impact of patenting on new product introductions in the pharmaceutical industry. (2007) . Working paper, Georgia Institute of Technology, AtlantaCrossref, Google Scholar
• Guedj I., Scharfstein D. Organizational scope and investment: Evidence from the drug development strategies and performance of biopharmaceutical firms. (2004) . NBER Working Paper 10933, National Bureau of Economic Research, Cambrige, MACrossref, Google Scholar
• Helfat C. E. Know-how and asset complementarity and dynamic capability accumulation: The case of R&D. Strategic Management J. (1997) 18(5):339–360Crossref, Google Scholar
• Henderson R. M. Underinvestment and incompetence as responses to radical innovation—Evidence from the photolithographic alignment equipment industry. RAND J. Econom. (1993) 24(2):248–270Crossref, Google Scholar
• Henderson R. M. Of life-cycles real and imaginary—The unexpectedly long old-age of optical lithography. Res. Policy (1995) 24(4):631–643Crossref, Google Scholar
• Henderson R. M., Clark K. B. Architectural innovation: The reconfiguration of existing product technologies and the failure of established firms. Admin. Sci. Quart. (1990) 35(1):9–30Crossref, Google Scholar
• Henderson R. M., Orsenigo L., Pisano G., Mowery D. C., Nelson R. R. The pharmaceutical industry and the revolution in molecular biology: Interactions among scientific, institutional, and organizational change. Sources of Industrial Leadership (1999) (Cambridge University Press, Cambridge, UK) 267–311Crossref, Google Scholar
• International Business Machines (IBM) History of IBM. () . Accessed November 4, 2005, http://www-03.ibm.com/ibm/history/history/history_intro.htmlGoogle Scholar
• Klepper S., Simons K. L. Dominance by birthright: Entry of prior radio producers and competitive ramifications in the US television receiver industry. Strategic Management J. (2000) 21(10/11):997–1016Crossref, Google Scholar
• Lederman M. The early history of radiotherapy: 1895–1939. Internat. J. Radiation Oncology, Biol., Phys. (1981) 7(5):639–648Crossref, Google Scholar
• Lu Z. J., Comanor W. S. Strategic pricing of new pharmaceuticals. Rev. Econom. Statist. (1998) 80(1):108–118Crossref, Google Scholar
• Maddala G. S.Limited Dependent and Qualitative Variables in Econometrics (1983) (Cambridge University Press, Cambridge, UK) Crossref, Google Scholar
• Makadok R. Toward a synthesis of the resource-based and dynamic-capability views of rent creation. Strategic Management J. (2001) 22:387–401Crossref, Google Scholar
• Methe D., Swaminathan A., Mitchell W. The underemphasized role of established firms as the sources of major innovations. Indust. Corporate Change (1996) 5(4):1181–1203Crossref, Google Scholar
• Mitchell W. The dynamics of evolving markets: The effects of business sales and age on dissolutions and divestitures. Admin. Sci. Quart. (1994) 39(4):575–602Crossref, Google Scholar
• Montgomery C. A., Hariharan S. Diversified expansion by large established firms. J. Econom. Behav. Organ. (1991) 15:71–89Crossref, Google Scholar
• Montgomery C. A., Wernerfelt B. Diversification, ricardian rents, and Tobin's Q. RAND J. Econom. (1988) 19(4):623–632Crossref, Google Scholar
• Nature Nature milestones: DNA technologies. (2007) . Accessed April 24, 2009, http://www.nature.com/milestones/miledna/timeline.htmlGoogle Scholar
• Nature Reviews Cancer Nature milestones: Cancer. (2006) . Accessed April 24, 2009, http://www.nature.com/milestones/milecancer/timeline.htmlGoogle Scholar
• Orsenigo L.The Emergence of Biotechnology: Institutions and Markets in Industrial Innovation (1989) (Pinter Publishers, London) Google Scholar
• Papke L. E., Wooldridge J. Econometric methods for fractional response variables with an application to 401(k) plan participation rates. J. Appl. Econometrics (1996) 11:619–632Crossref, Google Scholar
• Rang H. P., Rang H. P. The drug discovery process: General principles and some case histories. Drug Discovery and Development: Technology in Transition (2006) (Churchill Livingstone, London) 43–56Google Scholar
• Roberts T. G., Goulart B. H., Squitieri L., Stallings S. C., Halpern E. F., Chabner B. A., Gazelle G. S., Finkelstein S. N., Clark J. W. Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. J. Amer. Medical Assoc. (2004) 292(17):2130–2140Crossref, Google Scholar
• Rothaermel F. T. Incumbent's advantage through exploiting complementary assets via interfirm cooperation. Strategic Management J. (2001) 22(6/7):687–699Crossref, Google Scholar
• Rumelt R. P. Diversification strategy and profitability. Strategic Management J. (1982) 3:359–369Crossref, Google Scholar
• Schumpeter J. A.The Theory of Economic Development (1934) (Harvard University Press, Cambridge, MA) Google Scholar
• Schumpeter J. A.Capitalism, Socialism and Democracy (1950) 3rd ed.(Harper, New York) Google Scholar
• Shepart C. R., Kassis J., Whaley D. L., Kim H. G., Wells A. PLC gamma contributes to metastasis of in situ-occurring mammary and prostate tumors. Oncogene (2007) 26(21):3020–3026Crossref, Google Scholar
• Sigelman L., Zeng L. Analyzing censored and sample-selected data with tobit and heckit models. Political Anal. (1999) 8(2):167–182Crossref, Google Scholar
• Silverman B. S. Technological resources and the direction of corporate diversification: Toward an integration of the resource-based view and transaction cost economics. Management Sci. (1999) 45(8):1109–1124Link, Google Scholar
• Sosa M. L. Decoupling market incumbency from organizational experience: A study of biotechnology's impact on the market for anti-cancer drugs. (2006) . Unpublished doctoral dissertation, Massachusetts Institute of Technology, Cambridge, MAGoogle Scholar
• Stephens Inc.Cancer, Revolutionary Therapies, Innovative Investment Opportunities (2002) 2nd ed.(Stephens Inc., Little Rock, AR) Google Scholar
• Teece D. J. Profiting from technological innovation: Implications for integration, collaboration, licensing and public policy. Res. Policy (1986) 15:285–305Crossref, Google Scholar
• Teece D. J., Pisano G., Shuen A. Dynamic capabilities and strategic management. Strategic Management J. (1997) 18(7):509–533Crossref, Google Scholar
• Tripsas M. Unraveling the process of creative destruction: Complementary assets and incumbent survival in the typesetter industry. Strategic Management J. (1997) 18:119–142Crossref, Google Scholar
• Tushman M., Anderson P. Technological discontinuities and organizational environments. Admin. Sci. Quart. (1986) 31(3):439–465Crossref, Google Scholar
• UBS Warburg The Cancer Matrix: Exploring the Future of Cancer Therapy. (2001) (UBS Warburg, Zurich) Google Scholar
• Utterback J. M.Mastering the Dynamics of Innovation (1994) (Harvard Business School Press, Boston) Google Scholar
• Weinberg R. A.Racing to the Beginning of the Road: The Search for the Origin of Cancer (1996) (W. H. Freeman and Company, New York) Google Scholar
• Winter S. G. Understanding dynamic capabilities. Strategic Management J. (2003) 24:991–995Crossref, Google Scholar
• Zubrod C. G. Historic milestones in curative chemotherapy. Seminars in Oncology (1979) 6(4):490–505Google Scholar